

PASTAN and CHOWDHURY  
Application No.: 09/581,345  
Page 2

PATENT

IN THE CLAIMS

Please **cancel** claim 122.

Please **amend** the claims as follows:

*503 E1*  
*AWFL - mesothelin*  
113. (Amended) An isolated antibody comprising a variable heavy ( $V_H$ ) chain and a variable light (" $V_L$ ") chain, which  $V_H$  and  $V_L$  chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

114. (Amended) An antibody of claim 113, wherein said  $V_H$  and  $V_L$  chains comprise framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).

115. (Amended) An antibody of claim 113, wherein said antibody is a single chain Fv ("scFv").

*D2*  
117. (Amended) An antibody of claim 116, wherein said peptide linker has the sequence of SEQ ID NO:6.

*US*  
118. (Amended) An scFv of claim 115, wherein said scFv has the sequence shown in Figure 1 (SEQ ID NO:5).

*5747654*  
*3*  
120. (Amended) A dsFv of claim 119, having a  $V_L$  chain containing a cysteine at position 42, 43, 44, 45, 46, 98, 99, 100, or 101, such positions being determined in accordance with the numbering scheme published by Kabat and Wu, and a  $V_H$  chain containing a cysteine at position 43, 44, 45, 46, 47, 103, 104, 105 or 106, such positions being determined in accordance with the numbering scheme published by Kabat and Wu. *As set forth in patent*

121. (Amended) An antibody of claim 113, wherein said  $V_H$  and  $V_L$  chains are encoded by SEQ ID NO:1.

PASTAN and CHOWDHURY  
Application No.: 09/581,345  
Page 3

PATENT

SUB E2  
135. (Amended) An isolated antibody comprising a variable heavy ("V<sub>H</sub>") chain which V<sub>H</sub> chain has complementarity-determining regions as set forth in Figure 1 (SEQ ID NO:5).  
anti-mesothelin

136. (Amended) An antibody of claim 135, wherein said V<sub>H</sub> chain has the sequence set forth in Figure 1 (SEQ ID NO:5).

SUB E3  
140. (Amended) An isolated antibody comprising a variable light ("V<sub>L</sub>") chain which V<sub>L</sub> chain has complementarity-determining regions as set forth in Figure 1 (SEQ ID NO:5).  
anti-mesothelin

141. (Amended) An antibody of claim 140, wherein said V<sub>L</sub> chain has the sequence set forth in Figure 1 (SEQ ID NO:5).

D6  
145. (Amended) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable label attached or fused to an anti-mesothelin antibody comprising a variable heavy ("V<sub>H</sub>") chain and a variable light ("V<sub>L</sub>") chain, which V<sub>H</sub> and V<sub>L</sub> chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

146. (Amended) A composition of claim 145, wherein said V<sub>H</sub> and V<sub>L</sub> chains comprise framework regions ("FRs") as shown in Figure 1 (SEQ ID NO:5).

147. (Amended) A composition of claim 145, wherein said antibody is a single chain Fv ("scFv").

D7  
149. (Amended) A composition of claim 145, wherein said peptide linker has the sequence of SEQ ID NO:6.

PASTAN and CHOWDHURY  
Application No.: 09/581,345  
Page 4

PATENT

D7  
W

150. (Amended) A composition of claim 147, wherein said scFv has the sequence shown in Figure 1 (SEQ ID NO:5).

---

D8

154. (Amended) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable label attached or fused to an anti-mesothelin antibody comprising a variable heavy ("V<sub>H</sub>") chain having complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

---

155. (Amended) A composition of claim 154, wherein said V<sub>H</sub> chain comprises framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).

---

D9

158. (Amended) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable label attached or fused to an anti-mesothelin antibody comprising a variable light ("V<sub>L</sub>") chain having complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

---

159. (Amended) A composition of claim 158, wherein said V<sub>L</sub> chain comprises framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).

---

162. (Amended) A kit for detecting mesothelin on the surface of cells, said kit comprising:

D10

(i) anti-mesothelin antibody comprising a variable heavy (V<sub>H</sub>) chain and a variable light ("V<sub>L</sub>") chain, which V<sub>H</sub> and V<sub>L</sub> chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5); and,

(ii) instructions printed on a tangible medium, said instructions describing methods of using and said antibody for detecting mesothelin on the surface of cells.